Document is current
Any future updates will be listed below
-
Authors
Davis, Timothy M. E.
Giczewska, Anna
Lokhnygina, Yuliya
Mentz, Robert J.
Sattar, Naveed
Holman, Rury R.
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01144338 at ClinicalTrials.govDocuments that mention this clinical trial
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol
https://doi.org/10.1136/bmjopen-2014-005942
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
https://doi.org/10.2337/ds16-0026
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
https://doi.org/10.2337/dc18-2028
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (Results)
https://doi.org/10.2337/dc19-0950
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
https://doi.org/10.1186/s12933-019-0942-x
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
https://doi.org/10.1016/j.clinthera.2014.11.008
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
https://doi.org/10.2337/dc18-1871
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
https://doi.org/10.1016/s0140-6736(12)61267-7
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
https://doi.org/10.2337/dc19-1065
Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL (Results)
https://doi.org/10.2337/dc19-1079
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
https://doi.org/10.1186/s12933-022-01555-z
-
Funding
Funding for this research was provided by:
Amylin Pharmaceuticals
- License Information
-
More Information
Article History
Received: 10 March 2022
Accepted: 14 June 2022
First Online: 27 June 2022
Declarations
:
: Ethics committees at each participating site approved the protocol. All participants provided written informed consent.
: Not applicable.
: TMED has received grants and personal fees from Novo Nordisk, AstraZeneca, Merck, Boehringer-Ingelheim and Novartis. RJM received research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, and Windtree Therapeutics. NS has provided consulting or served on a speaker’s bureau for Amgen, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Pfizer and Sanofi and has received research support from Boehringer Ingelheim. RRH reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Bayer, Merck Sharp & Dohme, Novartis and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.
